2024
Jones MF, Smith CC. Mechanisms of Resistance to Targeted Therapies in AML. Annual Review of Cancer Biology. 2024 Jun 12; 8(1):81-96.
Levis M, Perl A, Schiller G, Fathi AT, Roboz G, Wang ES, Altman J, Rajkhowa T, Ando M, Suzuki T, Subach RA, Maier G, Madden T, Johansen M, Cheung K, Kurman M, Smith C. A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia. Blood Adv. 2024 May 28;8(10):2527-2535. doi: 10.1182/bloodadvances.2023010619. PMID: 38502195; PMCID: PMC11131057.
2023
Kennedy VE, Smith CC. FLT3 targeting in the modern era: from clonal selection to combination therapies. Int J Hematol. 2023 Dec 19. doi: 10.1007/s12185-023-03681-0. Epub ahead of print. PMID: 38112995.
Popescu B, Stahlhut C, Tarver TC, Wishner S, Lee BJ, Peretz CAC, Luck C, Phojanakong P, Camara Serrano JA, Hongo H, Rivera JM, Xirenayi S, Chukinas JA, Steri V, Tasian SK, Stieglitz E, Smith CC. Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML. Cell Rep Med. 2023 Nov 21;4(11):101290. doi: 10.1016/j.xcrm.2023.101290. PMID: 37992684; PMCID: PMC10694768.
Mandal K, Wicaksono G, Yu C, Adams JJ, Hoopmann MR, Temple WC, Izgutdina A, Escobar BP, Gorelik M, Ihling CH, Nix MA, Naik A, Xie WH, Hübner J, Rollins LA, Reid SM, Ramos E, Kasap C, Steri V, Serrano JAC, Salangsang F, Phojanakong P, McMillan M, Gavallos V, Leavitt AD, Logan AC, Rooney CM, Eyquem J, Sinz A, Huang BJ, Stieglitz E, Smith CC, Moritz RL, Sidhu SS, Huang L, Wiita AP. Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target. Nat Cancer. 2023 Nov;4(11):1592-1609. doi: 10.1038/s43018-023-00652-6. Epub 2023 Oct 30. PMID: 37904046; PMCID: PMC10663162.
Joshi SK, Pittsenbarger J, Kennedy VE, Peretz CAC, Perl AE, Smith CC, Tyner JW, Druker BJ, Traer E. The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib. Am J Hematol. 2023 Dec;98(12):E364-E368. doi: 10.1002/ajh.27096. Epub 2023 Oct 10. PMID: 37815132; PMCID: PMC10842343.
Huang LW, Shi Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Boscardin WJ, Steinman MA, Olin RL. Association of geriatric measures and global frailty with cognitive decline after allogeneic hematopoietic cell transplantation in older adults. J Geriatr Oncol. 2023 Nov;14(8):101623. doi: 10.1016/j.jgo.2023.101623. Epub 2023 Sep 6. PMID: 37678052; PMCID: PMC11101048.
Clark IC, Fontanez KM, Meltzer RH, Xue Y, Hayford C, May-Zhang A, D'Amato C, Osman A, Zhang JQ, Hettige P, Ishibashi JSA, Delley CL, Weisgerber DW, Replogle JM, Jost M, Phong KT, Kennedy VE, Peretz CAC, Kim EA, Song S, Karlon W, Weissman JS, Smith CC, Gartner ZJ, Abate AR. Microfluidics-free single-cell genomics with templated emulsification. Nat Biotechnol. 2023 Nov;41(11):1557-1566. doi: 10.1038/s41587-023-01685-z. Epub 2023 Mar 6. PMID: 36879006; PMCID: PMC10635830.
Peretz CAC, Kennedy VE, Walia A, Delley CL, Koh A, Tran E, Clark IC, Hayford CE, D'Amato C, Xue Y, Fontanez KM, Roy R, Logan AC, Perl AE, Abate A, Olshen A, Smith CC. Multiomic Single Cell Sequencing Identifies Stemlike Nature of Mixed Phenotype Acute Leukemia and Provides Novel Risk Stratification. bioRxiv [Preprint]. 2023 May 18:2023.05.15.540305. doi: 10.1101/2023.05.15.540305. PMID: 37292835; PMCID: PMC10245585.
2022
Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, McCloskey J, Smith CC, Schiller G, Bradley T, Tiu RV, Naqvi K, Dail M, Brackman D, Siddani S, Wang J, Chyla B, Lee P, Altman JK. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. J Clin Oncol. 2022 Jul 18;:JCO2200602. doi: 10.1200/JCO.22.00602. [Epub ahead of print] PubMed PMID: 35849791.
Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Huang CY, Olin RL. Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults. Transplant Cell Ther. 2022 Jun;28(6):309.e1-309.e9. doi: 10.1016/j.jtct.2022.02.022. Epub 2022 Mar 3. PubMed PMID: 35247612; PubMed Central PMCID: PMC9198006.
Perl AE, Hosono N, Montesinos P, Podoltsev N, Martinelli G, Panoskaltsis N, Recher C, Smith CC, Levis MJ, Strickland S, Röllig C, Groß-Langenhoff M, Chou WC, Lee JH, Yokoyama H, Hasabou N, Lu Q, Tiu RV, Altman JK. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. Blood Cancer J. 2022 May 30;12(5):84. doi: 10.1038/s41408-022-00677-7. PubMed PMID: 35637252; PubMed Central PMCID: PMC9151663.
Ferng TT, Terada D, Ando M, Tarver TC, Chaudhary F, Lin KC, Logan AC, Smith CC. The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms. Mol Cancer Ther. 2022 May 4;21(5):844-854. doi: 10.1158/1535-7163.MCT-21-0317. PubMed PMID: 35395091; PubMed Central PMCID: PMC9081245.
Smith CC, Levis MJ, Perl AE, Hill JE, Rosales M, Bahceci E. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022 Apr 12;6(7):2144-2155. doi: 10.1182/bloodadvances.2021006489. PubMed PMID: 35130342; PubMed Central PMCID: PMC9006281.
2021
James AJ, Smith CC, Litzow M, Perl AE, Altman JK, Shepard D, Kadokura T, Souda K, Patton M, Lu Z, Liu C, Moy S, Levis MJ, Bahceci E. Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. Clin Pharmacokinet. 2021 Sep;60(9):1251. doi: 10.1007/s40262-021-01060-8. PubMed PMID: 34297319; PubMed Central PMCID: PMC8416867.
Tran TH, Nguyen JV, Stecula A, Akutagawa J, Moorman AV, Braun BS, Sali A, Mullighan CG, Shah NP, Dai Y, Devidas M, Roberts KG, Smith CC, Loh ML. The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment. Haematologica. 2021 Aug 1;106(8):2242-2245. doi: 10.3324/haematol.2020.261354. PubMed PMID: 33626861; PubMed Central PMCID: PMC8327742.
Smith CC, Viny AD, Massi E, Kandoth C, Socci ND, Rapaport F, Najm M, Medina-Martinez JS, Papaemmanuil E, Tarver TC, Hsu HH, Le MH, West B, Bollag G, Taylor BS, Levine RL, Shah NP. Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Clin Cancer Res. 2021 Jul 15;27(14):4003-4011. doi: 10.1158/1078-0432.CCR-20-3458. Epub 2021 Jun 8. PubMed PMID: 34103301; PubMed Central PMCID: PMC8282743.
Demaree B, Delley CL, Vasudevan HN, Peretz CAC, Ruff D, Smith CC, Abate AR. Joint profiling of DNA and proteins in single cells to dissect genotype-phenotype associations in leukemia. Nat Commun. 2021 Mar 11;12(1):1583. doi: 10.1038/s41467-021-21810-3. PubMed PMID: 33707421; PubMed Central PMCID: PMC7952600.
Peretz CAC, McGary LHF, Kumar T, Jackson H, Jacob J, Durruthy-Durruthy R, Levis MJ, Perl A, Huang BJ, Smith CC. Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib. Blood Adv. 2021 Mar 9;5(5):1437-1441. doi: 10.1182/bloodadvances.2020003398. PubMed PMID: 33666651; PubMed Central PMCID: PMC7948271.
2020
Kennedy VE, Smith CC. FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies. Front Oncol. 2020;10:612880. doi: 10.3389/fonc.2020.612880. eCollection 2020. Review. PubMed PMID: 33425766; PubMed Central PMCID: PMC7787101.
James AJ, Smith CC, Litzow M, Perl AE, Altman JK, Shepard D, Kadokura T, Souda K, Patton M, Lu Z, Liu C, Moy S, Levis MJ, Bahceci E. Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. Clin Pharmacokinet. 2020 Oct;59(10):1273-1290. doi: 10.1007/s40262-020-00888-w. PubMed PMID: 32304015; PubMed Central PMCID: PMC7550323.
Smith CC. FLT3 Inhibition in Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2020 Sep;20 Suppl 1:S5-S6. doi: 10.1016/S2152-2650(20)30441-9. PubMed PMID: 32862867.
Smith CC, Levis MJ, Frankfurt O, Pagel JM, Roboz GJ, Stone RM, Wang ES, Severson PL, West BL, Le MH, Kayser S, Lam B, Hsu HH, Zhang C, Bollag G, Perl AE. A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia. Blood Adv. 2020 Apr 28;4(8):1711-1721. doi: 10.1182/bloodadvances.2020001449. PubMed PMID: 32330242; PubMed Central PMCID: PMC7189289.
Tarver TC, Hill JE, Rahmat L, Perl AE, Bahceci E, Mori K, Smith CC. Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations. Blood Adv. 2020 Feb 11;4(3):514-524. doi: 10.1182/bloodadvances.2019000919. PubMed PMID: 32040554; PubMed Central PMCID: PMC7013266.
Chao AK, Meyer JA, Lee AG, Hecht A, Tarver T, Van Ziffle J, Koegel AK, Golden C, Braun BS, Sweet-Cordero EA, Smith CC, Dvorak CC, Loh ML, Stieglitz E. Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing. Leukemia. 2020 Feb;34(2):662-666. doi: 10.1038/s41375-019-0549-y. Epub 2019 Sep 12. PubMed PMID: 31511612; PubMed Central PMCID: PMC6995757.
Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Steinman MA, Huang CY, Olin RL. Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients. Biol Blood Marrow Transplant. 2020 Jan;26(1):189-196. doi: 10.1016/j.bbmt.2019.08.022. Epub 2019 Sep 5. PubMed PMID: 31493541; PubMed Central PMCID: PMC6942208.
2019
Smith CC. The growing landscape of FLT3 inhibition in AML. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):539-547. doi: 10.1182/hematology.2019000058. Review. PubMed PMID: 31808872; PubMed Central PMCID: PMC6913436.
McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ, Pellegrino M, Durruthy-Durruthy R, Watt CD, Asthana S, Lasater EA, DeFilippis R, Peretz CAC, McGary LHF, Deihimi S, Logan AC, Luger SM, Shah NP, Carroll M, Smith CC, Perl AE. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. Cancer Discov. 2019 Aug;9(8):1050-1063. doi: 10.1158/2159-8290.CD-18-1453. Epub 2019 May 14. PubMed PMID: 31088841.
Smith CC. Roman warfare: targeting of support cells in AML. Blood. 2019 Feb 7;133(6):506-507. doi: 10.1182/blood-2018-12-887497. PubMed PMID: 30733203.
2018
Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Krämer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018 Jul;19(7):889-903. doi: 10.1016/S1470-2045(18)30240-7. Epub 2018 May 31. PubMed PMID: 29859851; PubMed Central PMCID: PMC8152787.
2017
Ferng T, Tarver T, Smith C. The Novel, Irreversible FLT3 Inhibitor FF-10101 Demonstrates Broad in Vitro Activity Against FLT3 Inhibitor Resistance Mutations. Blood. 2017 December; 130(Suppl 1):2632.
Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20. PubMed PMID: 28645776; PubMed Central PMCID: PMC5572576.
Smith CC, Paguirigan A, Jeschke GR, Lin KC, Massi E, Tarver T, Chin CS, Asthana S, Olshen A, Travers KJ, Wang S, Levis MJ, Perl AE, Radich JP, Shah NP. Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. Blood. 2017 Jul 6;130(1):48-58. doi: 10.1182/blood-2016-04-711820. Epub 2017 May 10. PubMed PMID: 28490572; PubMed Central PMCID: PMC5501146.
2016
Mannis GN, Martin TG 3rd, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis C. Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. Leuk Lymphoma. 2016 Jul;57(7):1560-6. doi: 10.3109/10428194.2015.1088646. Epub 2016 Jan 4. PubMed PMID: 26490487.
Lasater EA, Massi ES, Stecula A, Politi J, Tan SK, Smith CC, Gunthorpe M, Holmes JP, Chehab F, Sali A, Shah NP. Novel TKI-resistant BCR-ABL1 gatekeeper residue mutations retain in vitro sensitivity to axitinib. Leukemia. 2016 Jun;30(6):1405-9. doi: 10.1038/leu.2015.303. Epub 2015 Oct 29. PubMed PMID: 26511402.
Minson KA, Smith CC, DeRyckere D, Libbrecht C, Lee-Sherick AB, Huey MG, Lasater EA, Kirkpatrick GD, Stashko MA, Zhang W, Jordan CT, Kireev D, Wang X, Frye SV, Earp HS, Shah NP, Graham DK. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight. 2016 Mar;1(3):e85630. doi: 10.1172/jci.insight.85630. PubMed PMID: 27158668; PubMed Central PMCID: PMC4855528.
Ferng T, Smith CC. Resistance to FLT3 Inhibitors. In: Focosi D, editor. Resistance to Tyrosine Kinase Inhibitors Switzerland: Springer International Publishing; 2016. p.Pages 131-145.
2015
Nybakken GE, Canaani J, Roy D, Morrissette JD, Watt CD, Shah NP, Smith CC, Bagg A, Carroll M, Perl AE. Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone. Leukemia. 2016 Jun;30(6):1422-5. doi: 10.1038/leu.2015.320. Epub 2015 Nov 20. PubMed PMID: 26585411; PubMed Central PMCID: PMC4927337.
Smith C, Viny A, Massi E, Kandoth C, Socci N, Hsu H, West B, Bollag G, Taylor B, Levine R, Shah N. Recurrent Mutations in CCND3 Confer Clinical Resistance to FLT3 Inhibitors. Blood. 2015/12; 126(23):677.
Smith CC, Lin K, Stecula A, Sali A, Shah NP. FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors. Leukemia. 2015 Dec;29(12):2390-2. doi: 10.1038/leu.2015.165. Epub 2015 Jun 25. PubMed PMID: 26108694; PubMed Central PMCID: PMC4675689.
Frett B, McConnell N, Smith CC, Wang Y, Shah NP, Li HY. Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors. Eur J Med Chem. 2015 Apr 13;94:123-31. doi: 10.1016/j.ejmech.2015.02.052. Epub 2015 Feb 28. PubMed PMID: 25765758; PubMed Central PMCID: PMC4666306.
Smith CC, Zhang C, Lin KC, Lasater EA, Zhang Y, Massi E, Damon LE, Pendleton M, Bashir A, Sebra R, Perl A, Kasarskis A, Shellooe R, Tsang G, Carias H, Powell B, Burton EA, Matusow B, Zhang J, Spevak W, Ibrahim PN, Le MH, Hsu HH, Habets G, West BL, Bollag G, Shah NP. Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397. Cancer Discov. 2015 Jun;5(6):668-79. doi: 10.1158/2159-8290.CD-15-0060. Epub 2015 Apr 6. PubMed PMID: 25847190; PubMed Central PMCID: PMC4522415.
Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG 3rd. A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):377-83. doi: 10.1016/j.clml.2015.02.016. Epub 2015 Feb 14. PubMed PMID: 25776193.
2014
Warkentin AA, Lopez MS, Lasater EA, Lin K, He BL, Leung AY, Smith CC, Shah NP, Shokat KM. Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy. Elife. 2014 Dec 22;3. doi: 10.7554/eLife.03445. PubMed PMID: 25531068; PubMed Central PMCID: PMC4307180.
Mannis GN, Logan AC, Leavitt AD, Yanada M, Hwang J, Olin RL, Damon LE, Andreadis C, Ai WZ, Gaensler KM, Greene CC, Gupta NK, Kaplan LD, Mahindra A, Miyazaki Y, Naoe T, Ohtake S, Sayre PH, Smith CC, Venstrom JM, Wolf JL, Caballero L, Emi N, Martin TG. Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. Bone Marrow Transplant. 2015 Jan;50(1):40-4. doi: 10.1038/bmt.2014.201. Epub 2014 Sep 22. PubMed PMID: 25243620.
Chatterjee A, Ghosh J, Ramdas B, Mali RS, Martin H, Kobayashi M, Vemula S, Canela VH, Waskow ER, Visconte V, Tiu RV, Smith CC, Shah N, Bunting KD, Boswell HS, Liu Y, Chan RJ, Kapur R. Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis. Cell Rep. 2014 Nov 20;9(4):1333-48. doi: 10.1016/j.celrep.2014.10.039. Epub 2014 Nov 13. PubMed PMID: 25456130; PubMed Central PMCID: PMC4380442.
Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014 Jul;5(3):238-44. doi: 10.1016/j.jgo.2014.04.003. Epub 2014 Jun 2. PubMed PMID: 24894413.
Sudhindra A, Smith CC. FLT3 inhibitors in AML: are we there yet?. Curr Hematol Malig Rep. 2014 Jun;9(2):174-85. doi: 10.1007/s11899-014-0203-8. Review. PubMed PMID: 24682858.
Smith CC, Lasater EA, Lin KC, Wang Q, McCreery MQ, Stewart WK, Damon LE, Perl AE, Jeschke GR, Sugita M, Carroll M, Kogan SC, Kuriyan J, Shah NP. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5319-24. doi: 10.1073/pnas.1320661111. Epub 2014 Mar 12. PubMed PMID: 24623852; PubMed Central PMCID: PMC3986131.
2013
Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P, Cortes J, Kantarjian H, Shah NP. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leuk Res. 2014 Mar;38(3):316-22. doi: 10.1016/j.leukres.2013.12.006. Epub 2013 Dec 11. PubMed PMID: 24374145; PubMed Central PMCID: PMC4414320.
Smith CC. Disease diversity and FLT3 mutations. Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):20860-1. doi: 10.1073/pnas.1320579110. Epub 2013 Dec 9. PubMed PMID: 24324154; PubMed Central PMCID: PMC3876196.
Collins BH, Holzknecht ZE, Lynn KA, Sempowski GD, Smith CC, Liu S, Parker W, Rockey DC. Association of age-dependent liver injury and fibrosis with immune cell populations. Liver Int. 2013 Sep;33(8):1175-86. doi: 10.1111/liv.12202. Epub 2013 May 26. PubMed PMID: 23710620; PubMed Central PMCID: PMC4151465.
Smith CC, Lasater EA, Zhu X, Lin KC, Stewart WK, Damon LE, Salerno S, Shah NP. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood. 2013 Apr 18;121(16):3165-71. doi: 10.1182/blood-2012-07-442871. Epub 2013 Feb 21. PubMed PMID: 23430109; PubMed Central PMCID: PMC3630831.
Smith CC, Shah NP. The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. Am Soc Clin Oncol Educ Book. 2013;:313-8. doi: 10.14694/EdBook_AM.2013.33.313. Review. PubMed PMID: 23714533.
2012
Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, Perl AE, Travers KJ, Wang S, Hunt JP, Zarrinkar PP, Schadt EE, Kasarskis A, Kuriyan J, Shah NP. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012 Apr 15;485(7397):260-3. doi: 10.1038/nature11016. PubMed PMID: 22504184; PubMed Central PMCID: PMC3390926.
Smith CC, Shah NP. Mechanisms of resistance to targeted therapies in acute myeloid leukemia and chronic myeloid leukemia. Am Soc Clin Oncol Educ Book. 2012;:685-9. doi: 10.14694/EdBook_AM.2012.32.103. PubMed PMID: 24451819.
2011
Smith CC, Shah NP. Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia. Clin Cancer Res. 2011 Nov 1;17(21):6605-7. doi: 10.1158/1078-0432.CCR-11-2240. Epub 2011 Sep 26. PubMed PMID: 21948230.
Smith CC, Shah NP. Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease. Hematology Am Soc Hematol Educ Program. 2011;2011:121-7. doi: 10.1182/asheducation-2011.1.121. Review. PubMed PMID: 22160023.
2009
Kaimal AJ, Smith CC, Laros RK Jr, Caughey AB, Cheng YW. Cost-effectiveness of private umbilical cord blood banking. Obstet Gynecol. 2009 Oct;114(4):848-855. doi: 10.1097/AOG.0b013e3181b8fc0d. PubMed PMID: 19888044.